Aldeyra Therapeutics
ALDX
117 hedge funds and large institutions have $349M invested in Aldeyra Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 45 reducing their positions, and 34 closing their positions.
773% more call options, than puts
Call options by funds: $19.1M | Put options by funds: $2.18M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
9.9% less ownership
Funds ownership: 78.59% → 68.69% (-9.9%)
14% less funds holding
Funds holding: 136 → 117 (-19)
32% less capital invested
Capital invested by funds: $511M → $349M (-$162M)
33% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 45
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$3.62M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$2.85M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.7M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$2.39M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$16.4M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$9.27M |
| 3 |
Goldman Sachs
New York
|
-$8.13M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$5.22M |
| 5 |
AG
Artal Group
Luxembourg
|
-$4.89M |
ALDX Hedge Fund Activity: Q3 2021 in Review
117 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2021, worth a combined $349M — down 32% from $511M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ALDX and 16 opened new positions — a net loss of 18 holders — while 45 trimmed existing stakes and 30 added.
The largest buyer was Woodline Partners, adding an estimated $3.62M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $16.4M sold.
- 117 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2021, down from 136 in Q2 2021.
- Funds reported $349M of Aldeyra Therapeutics stock for Q3 2021, down 32% quarter-over-quarter.
- 16 funds opened new Aldeyra Therapeutics positions in Q3 2021 and 34 closed out, a net change of -18 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2021 was Woodline Partners, an estimated $3.62M added.
- The largest Aldeyra Therapeutics seller in Q3 2021 was Avidity Partners Management, an estimated $16.4M sold.
Based on aggregated 13F filings for Q3 2021.